Ingredion Q2 net sales rise 1% to $1.85 billion, but reported EPS falls to $1.78 from $2.99
Ingredion reported second quarter 2026 net sales of $1.85 billion, up 1% from a year earlier, while reported diluted EPS fell 40% to $1.78 and operating income fell 31% to $188 million. The company reaffirmed its amended full-year 2026 EPS guidance, which now reflects the sale of a majority stake in its Pakistan business, and said Tate & Lyle shareholders approved its all-cash offer on July 28, 2026.
Key points
- Q2 2026 reported diluted EPS was $1.78 versus $2.99 in Q2 2025; adjusted EPS was $2.82 versus $2.87.
- Full-year 2026 reported EPS guidance of $9.15 to $9.75 and adjusted EPS guidance of $10.30 to $10.90 were reaffirmed.
- Full-year 2026 cash from operations is now expected at $700 million to $800 million.
- Tate & Lyle shareholders approved Ingredion's 595 pence all-cash offer on July 28, 2026; the acquisition is pending.
The filing
Written by AI (Anthropic Claude, claude-haiku-5-5) on Nov 8, 2026, 12:58 AM ET, from the text of the filing and its press-release exhibits only. Written later: this filing was briefed after the fact, when past filings were added to the site, so the brief may be read with hindsight; the filing itself is the record of what was known on August 04, 2026.
Briefs are written by AI from the filing text (each brief's own page names the model) and can contain mistakes — open the filing before acting on anything. Impact (1-5) and tone are the model's reading of the filing for shareholders, not a price forecast. Not investment advice.